Skip to content

Technical Study: ACCU-CHEK Inform 3 (ACI 3) Pilot Study CIM RD003651

Technical Study: ACCU-CHEK Inform 3 (ACI 3) Pilot Study CIM RD003651 - ACI 3 Pilot Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON48319
Enrollment
200
Registered
2019-06-12
Start date
2019-06-25
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Geen speciale klasse, patienten met en zonder diabetes diabetes

Interventions

None listed

Sponsors

Roche Diagnostics GmbH
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adult Signed informed consent (before admittance to the ICU after scheduled operation). Diabetic and non-diabetic

Exclusion criteria

Exclusion criteria: Minor (

Design outcomes

Primary

MeasureTime frame
The primary research parameter is the blood glucose concentration. In the second phase of this study the accuracy of measurement of the ACI 3 will be determined. In the main phase, the performance of the ACI 3 on patient material is compared to the reference method. The results of this study will not be used for for regulatory submission or approval. If study results are deemed acceptable internally, a subsequent full performance evaluation study will take place.

Secondary

MeasureTime frame
In order to detect and explain possible interference, the percentage of hematocrit is also determined per patient (from material of the same sample). As additional information, the use of medication and, if determined, the diagnosis of 'diabetes' is also included. The sodium concentration and measured partial oxygen pressure (pO2) are only provided if a blood gas is routinely requested.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)